NCT05571345 - A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

December 23, 2022

Study Completion Date

December 28, 2022

Conditions

Recreational Drug Use

Interventions

DRUG

PF614

PF614 capsules (50 mg or 100 mg)

DRUG

Oxycodone Hydrochloride 40 mg

Oral 20 mg tablets (two each)

DRUG

Placebo

Placebo to match PF614 capsules will be provided by the sponsor.

Trial Locations (1)

Dr. Vince Clinical Research, Overland Park